Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial - Zhang, Changgong; Chen, Jianhua; Wu, Huijuan; Wang, Jun; Gao, Liying; Zhao, Jun; Sun, Yan; Jia, Zhongyao; Mu, Xinlin; Bai, Chunmei; Wang, Rui; Wu, Kailiang; et al. (Cancer pathogenesis and therapy, 2024)
Keywords: Anlotinib; Efficacy; Penpulimab; Phase II trial; Safety; Small cell lung cancer; Efficacy; Anlotinib; Small cell lung cancer; Penpulimab; Safety; Phase II trial